
- Vol 32 No 7
- Volume 32
- Issue 7
The 2015 International Congress on Schizophrenia Research
We are in the midst of a paradigm shift in the field, and new diagnostics and treatments that yield clinically significant improvement for the heterogeneous set of disorders known as schizophrenia are being developed.
Never discourage anyone who continually makes progress, no matter how slow.
-Plato
Recently, I attended the
[[{"type":"media","view_mode":"media_crop","fid":"24695","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_5918296671530","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4029","media_crop_rotate":"0","media_crop_scale_h":"100","media_crop_scale_w":"108","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"float: right;","title":" ","typeof":"foaf:Image"}}]]ICOSR Founding Directors,
I first attended the ICOSR in 2007 as a general psychiatry resident, thanks to the generous support of my mentors, and was honored to receive a Young Investigator award at the 2009 meeting. These two formative experiences certainly inspired and encouraged me in the pursuit of a career in schizophrenia research. The conference gathering every 2 years is a major opportunity to reach peers and take stock of where the field is heading. Schizophrenia researchers’ talent, dedication, and willingness to share knowledge are equally as impressive.
One sobering “take-home message,” however, was the absence of a major breakthrough in the pharmacological treatment of schizophrenia. I was struck by the symposium “Rising From the Ashes: How Do We Move Ahead on Novel Antipsychotic Drug Development?”1 The presenters critically reviewed recent so-called failed efforts to develop novel therapies for schizophrenia, including metabotropic glutamate receptor agonists, phosphodiesterase 10 inhibitors, glycine reuptake inhibitors, oxytocin, and intranasal insulin, and how we as a field might chart a path forward. That said, compelling information on the need for medications to decrease relapse as well as novel ways to monitor and reduce medication nonadherence-the major reason for relapse-were also presented.
We can learn just as much, if not more, from the failures as we do from the successes. As Aesop’s fable “The Tortoise and the Hare” reminds us, “slow and steady wins the race.” We are continuing to make incremental progress in many areas, including early detection, prevention, and intervention; risk factor epidemiology; genetics; endophenotypes; neuroinflammation; pharmacological and nonpharmacological treatments, including an increasing use of technology; and recognition and management of medical, psychiatric, and substance use comorbidities.
We are in the midst of a
Because I am a movie buff, let me offer an analogy between the ICOSR meeting and the Rocky films. Throughout the films, the heavyweight boxing champ Rocky must face his various fears and channel “the eye of the tiger.” In the same way, we need to set our sights on a goal and work for it with complete, unrelenting determination. When I think of 1000 bright, motivated schizophrenia researchers at the same venue, united in the common cause of improving quality of life for our patients with this devastating illness, I am inspired.
It is also great to see past recipients of the Young Investigator award grow over time in their research careers. Drs Schultz and Tamminga are leaving a legacy of energy and enthusiasm-our field’s own “eye of the tiger”-that we must continually harness as we strive toward game-changing findings regarding disease pathophysiology, diagnosis, and treatment. We need and have to do better for our patients, and I remain hopeful that we can and will succeed. More dedicated information about the ICOSR is available at
Disclosures:
1. Grace AA, Rasmussen K, Schmidt CJ, et al. Rising from the ashes: how do we move ahead on novel antipsychotic drug development?” Presented at: 15th International Congress on Schizophrenia Research; March 30, 2015; Colorado Springs, CO.
Articles in this issue
about 10 years ago
Cultural Issues in Treating Geriatric Patients With Mental Illnessabout 10 years ago
Pediatric ADHD and the Cultural Psychotherapeutic Modelabout 10 years ago
Cultural Competence and LGBT Issues in Psychiatryabout 10 years ago
Contemporary ECT for Depression Part 1: Practice Updateabout 10 years ago
Intervention Helps Workers With Depressionabout 10 years ago
Immigration and Post-Adolescent Psychology of Young Terroristsabout 10 years ago
Research That Can Change Clinical Practice in Psychotic Disordersabout 10 years ago
Perspectives on College Student Suicideabout 10 years ago
A Rational Suicide? Case Consultation and Quiz CommentaryNewsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.